Skinvisible Pharmaceuticals' sanitizer kills most H1N1
This article was originally published in The Tan Sheet
Executive SummaryThe Las Vegas-based firm says its hand sanitizer lotion DermSafe kills/inactivates the H1N1 virus to the same detection level as 70 percent alcohol, as demonstrated in clinical tests by Bioscience Laboratories. Skinvisible says the outcome confirms an in-vitro study conducted at the European contract research organization Retroscreen Virology, which found the product kills/inactivates 99.9 percent of H1N1. The firm adds the study "proves that Dermsafe is an effective alternative to alcohol, without the drying and safety issues." The sanitizer uses the firm's Invisicare polymer delivery system that binds to skin, resisting wash-off for up to four hours. FDA and the Federal Trade Commission have joined forces to crack down on marketing unapproved products making H1N1 claims (1"The Tan Sheet" Oct. 19, 2009)
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.